GPCRs: high-value targets in drug discovery

Introduction

G-Protein Coupled Receptors (GPCRs) represent the largest class of membrane proteins, characterized by seven transmembrane α-helices and domains that extend both inside and outside the cell. This unique structural arrangement enables GPCRs to receive external signals and translate them into precise cellular responses. GPCRs are involved in every aspect of human physiology demonstrating their therapeutic potential. Modulators of GPCRs have been developed as drug molecules for a wide range of therapeutic indications, including obesity, type-2 diabetes, cardiovascular diseases, Alzheimer’s disease, cancer, anti-psychotic therapies, inflammatory diseases, and migraine.

Why GPCRs Are Attractive Drug Targets

• Accessible Location: Positioned on the cell surface, making them readily accessible to drug molecules.

• Versatile Modulation: Can be modulated by a wide variety of chemical structures.

• Signaling Diversity: Involved in diverse signaling networks regulating numerous physiological processes.

GPCRs in Human Genome and Drug Development

• There are approximately 800 GPCRs in the human genome.

• Around 300 are promising targets for drug development.

• Currently, 516 approved drugs target 121 GPCRs.

• An additional 337 drugs are under development targeting 133 GPCRs.

Advances in Drug Discovery Targeting GPCRs

• High-Throughput Screening (HTS): Enabled by stable cell assays with improved signal detection.

• Structural breakthroughs using X-ray crystallography, Cryo-EM, and NMR have refined structure-based drug design (SBDD).

• Advanced computational tools to design potent and selective GPCR modulators (agonists/antagonists)

• Allosteric modulators, binding distinct from orthosteric sites, offer enhanced selectivity but face challenges due to limited structural information.

Drug Types:

• 71% of drugs in development are small molecules.

• Increasing development of peptide-, protein-, and antibody-based drugs.

Drug Repurposing:

• Of 337 drugs in clinical trials, 165 are approved for specific indications and are being tested for other indications

• Cannabidiol is being tested for 29 indications, highlighting cost-effective strategies.

Challenges and Opportunities

• Challenges include receptor dynamics, selectivity, and stringent safety regulations.

• Despite these hurdles, GPCRs hold immense clinical potential, driving ongoing innovative research worldwide.

Conclusion

GPCRs’ unique structural and signaling features, coupled with their crucial physiological roles, make them central to modern drug discovery efforts. Their continued exploration promises development of novel, targeted therapeutics.